Delivery Order SPE2DB20D3505-SPE2DB25FV1A0
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,943.19 on July 18, 2025, for the supply of Xeljanz XR 11 mg tablets (30-count units). This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, a leading pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $5,437.40 by the Defense Logistics Agency's Medical Supply Chain on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price, non-set-aside contract calls for the delivery of XELJANZ XR 11 mg tablets in quantities of 30 units. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,280.54 and is scheduled for completion by August 1, 2025. The contract represents a child award under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $3,198.50 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for XELJANZ XR 11 MG tablets in 30-count units. This is a firm fixed price, non-set-aside contract with performance completion scheduled for July 29, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location in the same city. The contract represents a child delivery order under...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Xeljanz 5 mg tablets. The $4,640.23 firm-fixed-price contract has an ultimate completion date of January 7, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency for XELJANZ XR 11 mg tablets in 30-count unit doses, valued at $18,565.52 under a firm fixed price contract type. The award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, carries no set-aside designation, indicating competitive award to this qualified pharmaceutical distributor. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,027.48 under a firm fixed-price contract type. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 tablets per unit. This competitively awarded, non-set-aside contract carries a firm fixed price ceiling value of $2,662.07 and is scheduled for completion by July 23, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a $20,369.56 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count packaging) on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price terms and represents a child delivery order under AmerisourceBergen's larger contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- Amerisourcebergen Drug Corp has received a firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical worth $7,573.25 to supply 11 mg Xeljanz XR tablets. As the prime contractor, Amerisourcebergen will deliver 30 units of the specified pharmaceutical product to the place of performance in Conshohocken, Pennsylvania by November 16, 2023. This order was awarded against an indefinite delivery contract held by Amerisourcebergen with no set-aside designation...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FV1A0Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, received a competitively awarded delivery order from the Defense Logistics Agency (DLA) on July 31, 2025, valued at $3,070.26 with a firm fixed price structure. The contract covers the delivery of Xeljanz 5 mg tablets in quantities of 60 units to support federal medical procurement needs. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. The award carried no set-aside designation, indicating it was awarded through open competition. The contract is scheduled for completion on August 1, 2025, with performance taking place in Conshohocken, Pennsylvania. Xeljanz is a targeted immunosuppressant medication used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the DLA's ongoing procurement of specialty pharmaceuticals to support Defense Health Agency operations and military healthcare systems. AmerisourceBergen's portfolio with the federal government demonstrates extensive experience fulfilling diverse pharmaceutical requirements across multiple therapeutic domains, from brand-name specialty medications to generic drugs and medical supplies, positioning the company as a critical vendor within the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 7/31/25 |